Details of the Drug Combinations

General Information of This Drug (ID: DM89QE1)

Drug Name
Metformin   DM89QE1
Synonyms
657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Metiguanide; Dimethylbiguanide; Glucophage; Haurymelin; Gliguanid; Fluamine; Glumetza; Flumamine; Melbin; Diabex; N,N-Dimethylbiguanide; Metformina; Metforminum; Metformine; Islotin; Glifage; Siofor; N1,N1-Dimethylbiguanide; DMGG; NNDG; Dimethyldiguanide; N,N-Dimethyldiguanide; Metformina [DCIT]; Imidodicarbonimidic diamide, N,N-dimethyl-; Metformina [Spanish]; Metforminum [INN-Latin]; Metformine [INN-French]; Metformin [USAN:INN:BAN]; 1,1-Dimethyl; Diabetosan; Dimethylbiguanidine; Dimethylguanylguanidine; Glycon; Diabex (TN); Diaformin (TN); Dianben (TN); Fortamet (TN); Gen-Metformin; Glucophage (TN); Glumetza (TN); LA-6023; Nu-Metformin; Obimet (TN); Riomet (TN); Metformin (USAN/INN); 1,1-Dimethyl biguanide; 3-(diaminomethylidene)-1,1-dimethylguanidine; [14C]metformin
Indication
Disease Entry ICD 11 Status REF
Colorectal carcinoma N.A. Approved [1]
Non-insulin dependent diabetes 5A11 Approved [1]
Ovarian serous cystadenocarcinoma N.A. Approved [1]
Prostate carcinoma N.A. Approved [1]
Type-2 diabetes 5A11 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Hypoglycemic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

185 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Metformin + Gefitinib DC1TQFZ Gefitinib Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + PD-0325901 DCP2IQW PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [4]
Metformin + PD-0325901 DC4Z6O0 PD-0325901 Adenocarcinoma (Cell Line: OVCAR3) [4]
Metformin + PD-0325901 DCXB88W PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + PD-0325901 DCZ6PF2 PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + PD-0325901 DCDA23D PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [4]
Metformin + PD-0325901 DC0WLO5 PD-0325901 Adenocarcinoma (Cell Line: DLD1) [4]
Metformin + PD-0325901 DCABTUY PD-0325901 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + PD-0325901 DCQO4R7 PD-0325901 Amelanotic melanoma (Cell Line: A2058) [4]
Metformin + PD-0325901 DCFGBHV PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + PD-0325901 DC0GG3I PD-0325901 Germ cell tumour (Cell Line: PA1) [4]
Metformin + PD-0325901 DCR0WZX PD-0325901 Malignant melanoma (Cell Line: HT144) [4]
Metformin + PD-0325901 DC3M1J1 PD-0325901 Malignant melanoma (Cell Line: SKMEL30) [4]
Metformin + PD-0325901 DCBBVT2 PD-0325901 Malignant melanoma (Cell Line: UACC62) [4]
Metformin + PD-0325901 DCG259W PD-0325901 Mesothelioma (Cell Line: MSTO) [4]
Metformin + PD-0325901 DCNBUPU PD-0325901 Non small cell carcinoma (Cell Line: SKMES1) [4]
Metformin + PD-0325901 DCWKVP3 PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Metformin + PD-0325901 DCSJBBW PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [4]
Metformin + PD-0325901 DCSC265 PD-0325901 Prostate carcinoma (Cell Line: VCAP) [4]
Metformin + Kanamycin DC2Z0KO Kanamycin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Lapatinib DCF6E8R Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + Lapatinib DCQJ959 Lapatinib Adenocarcinoma (Cell Line: SW-620) [4]
Metformin + Lapatinib DCP0YQP Lapatinib Germ cell tumour (Cell Line: PA1) [4]
Metformin + MK-1775 DCHG1K0 MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [4]
Metformin + MK-1775 DC5KMKA MK-1775 Adenocarcinoma (Cell Line: NCIH1650) [4]
Metformin + MK-1775 DC82WND MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + MK-1775 DCP2M11 MK-1775 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + MK-1775 DC80V1O MK-1775 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + MK-1775 DCKMZT6 MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + MK-1775 DCQUVN3 MK-1775 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Metformin + PMID28460551-Compound-2 DC8XTED PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + PMID28460551-Compound-2 DCDWI3U PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + PMID28460551-Compound-2 DCJW8DM PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + RTB101 DC4RKRJ RTB101 Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + RTB101 DCU8GWO RTB101 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + RTB101 DCB3ONA RTB101 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + RTB101 DCTXG0P RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + SCH-900776 DCKRSR0 SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + SCH-900776 DCJLVOI SCH-900776 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + SCH-900776 DCJLXTZ SCH-900776 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + SCH-900776 DCFSJ95 SCH-900776 Adenocarcinoma (Cell Line: SW-620) [4]
Metformin + SCH-900776 DCF0XTR SCH-900776 Malignant melanoma (Cell Line: HT144) [4]
Metformin + SCH-900776 DC3R3TU SCH-900776 Prostate carcinoma (Cell Line: LNCAP) [4]
Metformin + Triapine DCGUW3M Triapine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + SNX-2112 DCK74S0 SNX-2112 Adenocarcinoma (Cell Line: A427) [4]
Metformin + SNX-2112 DCYNWVJ SNX-2112 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + SNX-2112 DCEAP73 SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [4]
Metformin + BHV-0223 DCQQU9I BHV-0223 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Metyrosine DC0LAAI Metyrosine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + SCH 727965 DCXI6UM SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + SCH 727965 DCWMK6B SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + SCH 727965 DCAJO7N SCH 727965 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + SCH 727965 DCJNORO SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + SCH 727965 DCAPSCC SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [4]
Metformin + Erlotinib DCA2XMW Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + Erlotinib DCJ5SO7 Erlotinib Adenocarcinoma (Cell Line: HT29) [4]
Metformin + Erlotinib DCFEU8Q Erlotinib Adenocarcinoma (Cell Line: SW-620) [4]
Metformin + Erlotinib DCKFJPG Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + Erlotinib DC81PQ0 Erlotinib Mesothelioma (Cell Line: MSTO) [4]
Metformin + Daidzin DCJ3U7J Daidzin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + MK-5108 DCGTMIK MK-5108 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + MK-5108 DCW7HH5 MK-5108 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + MK-5108 DC0BD5V MK-5108 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + MK-5108 DCU9YJG MK-5108 Malignant melanoma (Cell Line: A375) [4]
Metformin + MK-5108 DCGBX6L MK-5108 Malignant melanoma (Cell Line: RPMI7951) [4]
Metformin + MK-5108 DC57WKU MK-5108 Malignant melanoma (Cell Line: UACC62) [4]
Metformin + MK-5108 DC1OVJ5 MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Metformin + Fibrates DCH4ZOP Fibrates Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Clopidogrel DC65ENX Clopidogrel Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Arfolitixorin DCZ7C5H Arfolitixorin Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Ridaforolimus DC2XSPE Ridaforolimus Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + Ridaforolimus DCEZXSM Ridaforolimus Adenocarcinoma (Cell Line: HT29) [4]
Metformin + MK-4827 DC3QMWE MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [4]
Metformin + MK-4827 DCJHU0K MK-4827 Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + MK-4827 DCIB4EE MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [4]
Metformin + MK-4827 DC4RJJL MK-4827 Adenocarcinoma (Cell Line: HCT116) [4]
Metformin + MK-4827 DC5NYRE MK-4827 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + MK-4827 DCVX14L MK-4827 Amelanotic melanoma (Cell Line: A2058) [4]
Metformin + MK-4827 DCV0NPE MK-4827 Malignant melanoma (Cell Line: SKMEL30) [4]
Metformin + MK-4827 DC0Y88K MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [4]
Metformin + MK-4827 DCFXORH MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Metformin + Idarubicin DCC1ZVH Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [4]
Metformin + Idarubicin DC5XSYW Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + Idarubicin DC2J9YO Idarubicin Adenocarcinoma (Cell Line: DLD1) [4]
Metformin + Idarubicin DCLTB88 Idarubicin Adenocarcinoma (Cell Line: HCT116) [4]
Metformin + Idarubicin DCWCFGH Idarubicin Adenocarcinoma (Cell Line: HT29) [4]
Metformin + Idarubicin DC7KSAM Idarubicin Germ cell tumour (Cell Line: PA1) [4]
Metformin + Idarubicin DCQLAMW Idarubicin Malignant melanoma (Cell Line: HT144) [4]
Metformin + Idarubicin DCYI5XV Idarubicin Malignant melanoma (Cell Line: SKMEL30) [4]
Metformin + Idarubicin DCJH73L Idarubicin Malignant melanoma (Cell Line: UACC62) [4]
Metformin + Idarubicin DCITYQF Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Metformin + Idarubicin DC2A9T6 Idarubicin Prostate carcinoma (Cell Line: VCAP) [4]
Metformin + Idarubicin DCASK83 Idarubicin Prostate carcinoma (Cell Line: LNCAP) [4]
Metformin + Bortezomib DC3M76V Bortezomib Amelanotic melanoma (Cell Line: A2058) [4]
Metformin + Bortezomib DCI23PH Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + Methylene blue DCHVV7T Methylene blue Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + GSK525762 DCSDAEM GSK525762 Adenocarcinoma (Cell Line: CAOV3) [4]
Metformin + GSK525762 DC4T3HR GSK525762 Adenocarcinoma (Cell Line: NCIH23) [4]
Metformin + GSK525762 DCBQNDW GSK525762 Adenocarcinoma (Cell Line: COLO320DM) [4]
Metformin + GSK525762 DC19W0D GSK525762 Adenocarcinoma (Cell Line: DLD1) [4]
Metformin + GSK525762 DCEH086 GSK525762 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + GSK525762 DC0QJTE GSK525762 Amelanotic melanoma (Cell Line: A2058) [4]
Metformin + GSK525762 DCT69VE GSK525762 Germ cell tumour (Cell Line: PA1) [4]
Metformin + GSK525762 DCLJ2R2 GSK525762 Malignant melanoma (Cell Line: RPMI7951) [4]
Metformin + GSK525762 DCKY3DH GSK525762 Malignant melanoma (Cell Line: SKMEL30) [4]
Metformin + GSK525762 DC7OTOE GSK525762 Malignant melanoma (Cell Line: UACC62) [4]
Metformin + GSK525762 DC7AINK GSK525762 Non small cell carcinoma (Cell Line: SKMES1) [4]
Metformin + GSK525762 DCVIDGB GSK525762 Prostate carcinoma (Cell Line: LNCAP) [4]
Metformin + Maprotiline DCXO3F2 Maprotiline Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Leflunomide DCEFXU3 Leflunomide Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Sorafenib DC1G3PU Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [4]
Metformin + Sorafenib DCC0DKT Sorafenib Adenocarcinoma (Cell Line: NCIH1650) [4]
Metformin + Sorafenib DCO2CUH Sorafenib Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + Sorafenib DCRYCN7 Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + Quinine DC0ZHL4 Quinine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + MK-2206 DCE0TF5 MK-2206 Adenocarcinoma (Cell Line: HT29) [4]
Metformin + MK-2206 DCPMMW1 MK-2206 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Metformin + MK-2206 DCAZPCM MK-2206 Malignant melanoma (Cell Line: A375) [4]
Metformin + MK-2206 DCJ05B9 MK-2206 Malignant melanoma (Cell Line: SKMEL30) [4]
Metformin + Mycophenolic acid DC6RZD7 Mycophenolic acid Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Cisatracurium DC9XMMZ Cisatracurium Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Mefloquine DCCVZ4F Mefloquine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + PMID28870136-Compound-43 DCS9MZ0 PMID28870136-Compound-43 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Hydroxychloroquine DCX7199 Hydroxychloroquine Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Aciclovir DC34BDD Aciclovir Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + GSK2194069 DC9MOMA GSK2194069 Chronic myelogenous leukemia (Cell Line: KBM-7) [4]
Metformin + Dasatinib DCT27YV Dasatinib Adenocarcinoma (Cell Line: A427) [4]
Metformin + Dasatinib DC37316 Dasatinib Adenocarcinoma (Cell Line: NCIH520) [4]
Metformin + Dasatinib DCIJ7VA Dasatinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Metformin + Dasatinib DCIEWQP Dasatinib Adenocarcinoma (Cell Line: HT29) [4]
Metformin + Dasatinib DCJ0PGD Dasatinib Adenocarcinoma (Cell Line: SW-620) [4]
Metformin + Dasatinib DCJ5T1P Dasatinib Malignant melanoma (Cell Line: SKMEL30) [4]
Metformin + Dasatinib DCFEFV6 Dasatinib Mesothelioma (Cell Line: MSTO) [4]
Metformin + Dasatinib DC2N4QX Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Metformin + Dasatinib DCJJNHX Dasatinib Prostate carcinoma (Cell Line: VCAP) [4]
Metformin + PD-0325901 DCOK0MR PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Metformin + PD-0325901 DCEGQNG PD-0325901 Breast carcinoma (Cell Line: KPL1) [5]
Metformin + PD-0325901 DC2CL7X PD-0325901 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + PD-0325901 DC9DG9K PD-0325901 Carcinoma (Cell Line: EFM192B) [5]
Metformin + PD-0325901 DC28IMT PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + Lapatinib DCJ8FKK Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + Lapatinib DCICXT3 Lapatinib Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + MK-1775 DCL3ITK MK-1775 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + RTB101 DCKNIBB RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Metformin + RTB101 DCEU735 RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + RTB101 DCNDSDS RTB101 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + RTB101 DCOJWZS RTB101 Carcinoma (Cell Line: OV90) [5]
Metformin + RTB101 DCE25JH RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + SCH-900776 DCTDXPS SCH-900776 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + SCH-900776 DCOJW2C SCH-900776 Carcinoma (Cell Line: EFM192B) [5]
Metformin + SCH-900776 DC1M9HC SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + SNX-2112 DCWMKUK SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Metformin + SNX-2112 DC3C2G8 SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + SNX-2112 DCT0SNM SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + SCH 727965 DC97D1X SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + SCH 727965 DCZC4LL SCH 727965 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + SCH 727965 DCKCT4P SCH 727965 Carcinoma (Cell Line: OV90) [5]
Metformin + SCH 727965 DCDLBW8 SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + Erlotinib DC1GB5N Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + Erlotinib DCTBIHC Erlotinib Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + MK-5108 DC4U3XU MK-5108 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + MK-5108 DC4NZTV MK-5108 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + MK-5108 DCTDOCN MK-5108 Colon carcinoma (Cell Line: RKO) [5]
Metformin + Ridaforolimus DCTVLJB Ridaforolimus Breast carcinoma (Cell Line: KPL1) [5]
Metformin + MK-4827 DCX0YG6 MK-4827 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + MK-4827 DCBNXOO MK-4827 Carcinoma (Cell Line: OV90) [5]
Metformin + Idarubicin DCLODDC Idarubicin Breast carcinoma (Cell Line: KPL1) [5]
Metformin + Idarubicin DC5MXH3 Idarubicin Carcinoma (Cell Line: MDAMB436) [5]
Metformin + Idarubicin DC3YCMC Idarubicin Colon carcinoma (Cell Line: RKO) [5]
Metformin + Idarubicin DCQYMFP Idarubicin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + Bortezomib DCLFJ1U Bortezomib Carcinoma (Cell Line: OV90) [5]
Metformin + GSK525762 DCJQN3R GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Metformin + GSK525762 DCIAPS8 GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + GSK525762 DCS1LBA GSK525762 Carcinoma (Cell Line: OV90) [5]
Metformin + GSK525762 DCPCAEQ GSK525762 Carcinoma (Cell Line: EFM192B) [5]
Metformin + GSK525762 DCA19FU GSK525762 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + Sorafenib DCYXW5Q Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + Sorafenib DCTGDZU Sorafenib Breast carcinoma (Cell Line: ZR751) [5]
Metformin + Sorafenib DC4KSKC Sorafenib Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + Sorafenib DCVIC7S Sorafenib Carcinoma (Cell Line: OV90) [5]
Metformin + Sorafenib DCM7QXP Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [5]
Metformin + MK-2206 DCVV3DN MK-2206 Breast carcinoma (Cell Line: OCUBM) [5]
Metformin + Dasatinib DCTKKFG Dasatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Metformin + Dasatinib DC8GAY2 Dasatinib Carcinoma (Cell Line: EFM192B) [5]
Metformin + Dasatinib DC6FWMW Dasatinib Carcinoma (Cell Line: MDAMB436) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 185 DrugCom(s)
36 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Metformin + Aspirin DC04PHO Aspirin Preeclampsia [6]
Metformin + Sitagliptin DCDEZAK Sitagliptin Type 2 Diabetes [7]
Metformin + Glipizide DCDS4EB Glipizide Type 2 Diabetes Mellitus [8]
Metformin + Colesevelam DCI79H1 Colesevelam Type 2 Diabetes [9]
Metformin + Saxagliptin DCJZJ9F Saxagliptin Type 2 Diabetes [10]
Metformin + Glipizide DCLUX8K Glipizide Type 2 Diabetes [11]
Metformin + Dapagliflozin DCMSNPO Dapagliflozin Type 2 Diabetes Mellitus [12]
Metformin + Acarbose DCP3JVE Acarbose Diabetes, Type 2 [13]
Metformin + Sitagliptin DCRRXIM Sitagliptin Type 2 Diabetes Mellitus [14]
Metformin + Dapagliflozin DCSEBNV Dapagliflozin Type 2 Diabetes [11]
Metformin + Eslicarbazepine acetate DCVSQJL Eslicarbazepine acetate Neuropathic Pain [15]
Metformin + Saxagliptin DCY4K9C Saxagliptin Type 2 Diabetes Mellitus [16]
Metformin + Linagliptin DCHU4XJ Linagliptin Diabetic complication [17]
Metformin + Rosiglitazone DCDFXP5 Rosiglitazone Advanced solid tumour; Diabetic complication [18]
Metformin + Canagliflozin DCDZWCY Canagliflozin Type-2 diabetes [19]
Metformin + Dapagliflozin DCH96ME Dapagliflozin Type-2 diabetes [20]
Metformin + L-leucine DCL18FJ L-leucine Type-2 diabetes [17]
Metformin + Sitagliptin DCRTDAX Sitagliptin Type-2 diabetes [17]
Metformin + Vildagliptin DCULQ98 Vildagliptin Type-2 diabetes [21]
Metformin + Vincristine DCHDW34 Vincristine Solid Tumors [22]
Metformin + Carboplatin DC3UILR Carboplatin Ovarian Papillary Serous Carcinoma [23]
Metformin + Isavuconazole DC8RR3V Isavuconazole Pharmacokinetics of Isavuconazole [24]
Metformin + Cytarabine DCFIG8O Cytarabine Adult Acute Megakaryoblastic Leukemia (M7) [25]
Metformin + Vandetanib DCPCRU5 Vandetanib Renal Cell Carcinoma [26]
Metformin + Cimetidine DCYY28M Cimetidine Interaction [27]
Metformin + Dapagliflozin DC8L29B Dapagliflozin Type 2 Diabetes [28]
Metformin + Ivermectin DCCBRXW Ivermectin Covid19 [29]
Metformin + Fluvoxamine DCFG5WZ Fluvoxamine Covid19 [29]
Metformin + Sitagliptin DC3BI0L Sitagliptin Type 2 Diabetes Mellitus [30]
Metformin + Dapagliflozin DC47MWP Dapagliflozin Diabetes Mellitus Type 2 [31]
Metformin + Exenatide DC4KY92 Exenatide Polycystic Ovary Syndrome [32]
Metformin + Voglibose DC7NJPF Voglibose Type 2 Diabetes Mellitus [33]
Metformin + Vildagliptin DCKZ2K3 Vildagliptin Coronary Artery Disease [34]
Metformin + ASP1941 DCL0PNL ASP1941 Type 2 Diabetes Mellitus [35]
Metformin + Canagliflozin DCRY3FB Canagliflozin Polycystic Ovary Syndrome [36]
Metformin + Clomifene DCTKP2Y Clomifene PCOS [37]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 DrugCom(s)
1 Approved Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Metformin + Empagliflozin DCBEIHD Empagliflozin Type-2 diabetes [38]
------------------------------------------------------------------------------------

References

1 Metformin FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. March 2020
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 ClinicalTrials.gov (NCT05580523) Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial
7 ClinicalTrials.gov (NCT00961480) A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)
8 ClinicalTrials.gov (NCT00856284) Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
9 ClinicalTrials.gov (NCT00951899) The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
10 ClinicalTrials.gov (NCT00661362) Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes
11 ClinicalTrials.gov (NCT00660907) Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
12 ClinicalTrials.gov (NCT00859898) Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes
13 ClinicalTrials.gov (NCT01624116) Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes
14 ClinicalTrials.gov (NCT00420511) Beta-Cell Function and Sitagliptin Trial (BEST)
15 ClinicalTrials.gov (NCT00971295) Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers
16 ClinicalTrials.gov (NCT00897390) Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 FDA Drug Development and Drug Interactions
19 ClinicalTrials.gov (NCT01508182) A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers. U.S. National Institutes of Health.
20 Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013 Feb 20;11:43.
21 ClinicalTrials.gov (NCT01518101) Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications. U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT01528046) Metformin in Children With Relapsed or Refractory Solid Tumors
23 ClinicalTrials.gov (NCT02050009) Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
24 ClinicalTrials.gov (NCT01884558) A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin
25 ClinicalTrials.gov (NCT01849276) Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
26 ClinicalTrials.gov (NCT02495103) Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
27 ClinicalTrials.gov (NCT05365451) Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters
28 ClinicalTrials.gov (NCT01606007) Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
29 ClinicalTrials.gov (NCT04510194) COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
30 ClinicalTrials.gov (NCT01709305) A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
31 ClinicalTrials.gov (NCT02719132) Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
32 ClinicalTrials.gov (NCT04029272) Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients
33 ClinicalTrials.gov (NCT02049814) Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
34 ClinicalTrials.gov (NCT03693560) Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD
35 ClinicalTrials.gov (NCT03118713) A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
36 ClinicalTrials.gov (NCT06256289) Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
37 ClinicalTrials.gov (NCT04010942) Vitamin D for Polycystic Ovary Syndrome Clomiphene Resistant Women
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030467)